Aarhus University Seal

The IMAPD project aims to define immune-related biomarkers in the blood of patients with Parkinson's disease (PD). The IMPAD team hopes that these biomarkers can be used as proxies for brain events, markers of progression and possible therapeutic targets in PD. In parallel with these studies, the team will also assess the translational potential of both cellular and animal PD models. Lundbeck is industry partner in the IMPAD project.

On this page, you can find all of the news from ODIN, which is related to the IMPAD project. You are always welcome to contact Head of the IMPAD project Marina Romero-Ramos, if you are looking for more information.

IMPAD is short for "IMmune-related biomarkers and targets in PArkinson's Disease"

Main contact for the IMPAD project

Company involved in the IMPAD project

Our OPEN approach to innovation in science

In ODIN, all findings and results will be shared openly. 

Researchers working on ODIN projects are encouraged to upload all of their findings to the ODIN community on Zenodo - see the link to the right.

If you have any questions, you are more than welcome to contact the ODIN secretariat.